Author(s): Swalin Parija, Guru Prasad Mohanta, Upendra Nath Nanda, V. Saikishore

Email(s): swalinpharma@gmail.com

DOI: 10.52711/0974-360X.2022.00764   

Address: Swalin Parija1*, Guru Prasad Mohanta2, Upendra Nath Nanda3, V. Saikishore4
1Institute of Pharmacy and Technology, Salipur, Cuttack, Odisha - 754202.
2Annamalai University, Annamalai Nagar, Tamil Nadu – 608002.
3Seemanta Institute of Pharmaceutical Sciences, Jharpokharia, Mayurbhanj, Odisha – 757086.
4Department of Pharmaceutics, Bapatla College of Pharmacy, Bapatla, A.P. - 522101.
*Corresponding Author

Published In:   Volume - 15,      Issue - 10,     Year - 2022


ABSTRACT:
Budesonide is widely used drug for treatment of active inflammatory bowel disease (IBD). Core in-cup tablets were prepared to achieve a prolonged release of Budesonide and for alleviating the symptoms of inflammatory bowel disease. The objective of this study was to investigate differences in the pharmacokinetic patterns between an optimized core in cup tablet formulation and pure Budesonide suspension. In-vivo evaluation studies were performed based on the uniform and reliable results of in-vitro drug release studies. Various pharmacokinetic parameters were compared to obtain mean plasma drug concentration curve versus time. The pure drug suspension and Core-in-cup tablets formulation of Budesonide were administered to two groups of white New Zealand rabbits (n=6) through the oral route following cross over design pattern. The drug concentration in plasma samples were measured using LC-MS/MS method. Pharmacokinetic parameters were determined for each formulation. The comparison of the plasma time curves of the dosage forms showed that each dosage form caused significant differences in the drug plasma levels. The optimized core in cup tablet formulation shown some lag phase initially before releasing the drug. The mean residence time of core in cup tablet formulation was found to be more than the pure drug suspension formulation. The oral administration of Budesonide resulted in a low and quite variable AUC of 154.1±1.44 ng/ml/hr., whereas the optimized core-in-cup tablets resulted in AUC of 918.2±3.11 ng/ml/hr. The bioavailability of optimized formulation was enhanced six times compared with pure drug suspension. From the above results, it can be concluded that the prepared core in cup tablet can be considered as one of the promising formulation techniques for chronotherapeutic management of inflammatory bowel disease.


Cite this article:
Swalin Parija, Guru Prasad Mohanta, Upendra Nath Nanda, V. Saikishore. Design, Development and In vivo Evaluation of Core in Cup Tablets of Budesonide. Research Journal of Pharmacy and Technology2022; 15(10):4553-8. doi: 10.52711/0974-360X.2022.00764

Cite(Electronic):
Swalin Parija, Guru Prasad Mohanta, Upendra Nath Nanda, V. Saikishore. Design, Development and In vivo Evaluation of Core in Cup Tablets of Budesonide. Research Journal of Pharmacy and Technology2022; 15(10):4553-8. doi: 10.52711/0974-360X.2022.00764   Available on: https://rjptonline.org/AbstractView.aspx?PID=2022-15-10-37


REFERENCE:
1.    Sumithra S, Vadivu R, Radha R. Colon Targeted Drug Delivery System of Phytoconstituents. . Research Journal of Pharmacy and Technology. 2019 July1; 12(7):3144-3150. doi: 10.5958/0974-360X.2019.00530.4 9.
2.    Malayandi R, Kondamudi P, Ruby PK, Aggarwal D. Biopharmaceutical considerations and characterizations in development of colon targeted dosage forms for inflammatory bowel disease. Drug Delivery and Translational Research. 2014 Apr 4 ;4(2):187–202. doi: 10.1007/s13346-013-0185-4.
3.    Syam Prasad B, Chinna Eswaraiah M, Kamalakar Reddy G. Effect of Polysorbate 80 and Particle Size of Budesonide API on In-vitro Dissolution Profiles of Budesonide MUPS Tablets 9 mg. Research Journal of Pharmacy and Technology. 2018 Oct 10; 11(10): 4285-4295. doi: 10.5958/0974-360X.2018.00785.0
4.    Anuja Kolsure, Kratika Daniel, Mahesh Bhat. Analytical methods for estimation of Budesonide in bulk and in Pharmaceutical dosage forms: A Review. Research Journal of Pharmacy and Technology. 2021May1; 14(5):2873-7. doi: 10.52711/0974-360X.2021.00505
5.    Saikishore V, Vamsi Krishna B, Babu Rao Ch. Design and Development of Pulsatile drug delivery of Diltiazem Hydrochloride. Research Journal of Pharmacy and Technology. 2020 Jun16; 13(5):2315-2320. doi:10.5958/0974-360X.2020.00417.5
6.    Shashikala P, Sireesha D, Vasudha B. Development and Validation of Bioanalytical Method for the Estimation of Carisoprodol in Human Plasma using LC-MS/MS. Asian Journal of Pharmaceutical Analysis. 2015; Apr12; 5(4): 5: 181-186. doi: 10.5958/2231-5675.2015.00029.0.
7.    Pramod K, Amar Deep A, Pooja K, Mahendra Singh A. An Overview: LC-MS as Tool of sample Extraction and Quantification in Bioanalytical Laboratories. Asian Journal of Pharmaceutical Analysis. 2020 Mar1;10(3):165-172. doi: 10.5958/2231-5675.2020.00030.7
8.    Surendran V, Anoop S, Sampathkumar KP. Pharmacokinetic Study of Oxime Prodrug of Gliclazide by LC-MS/MS Method in Rabbit Plasma. Asian Journal of Research in Chemistry.2015 May 1; 8(5): 351-357. doi: 10.5958/0974-4150.2015.00058.9
9.    Sambasiva Rao P, Nithya G. A Sensitive, Rapid Determination of Moxonidine in Plasma by LC-MS/MS, Application to Bioequivalence Study. Research Journal of Pharmacy and Technology. 2020 Dec1; 13(12):5773-5776. doi: 10.5958/0974-360X.2020.01006.9
10.    Francis M, Balamurali MM, Mohanlal S, Rajendra Prasad M. Development and Validation of Highly Sensitive HPLC-Ms/Ms Method for the Determination of Duloxetine in Human Plasma and its Application to Clinical Pharmacokinetic Study by Assessing Multiple Bioequivalence Approaches. Research Journal of Pharmacy and Technology. 2020 May 1; 13(5):2117-2124. doi: 10.5958/0974-360X.2020.00381.9.
11.    Sai Sheela A, Mathrusri Annapurna M, Spandana Yasaswini R. New validated stability indicating RP-UFLC method for the determination of Budesonide. Research Journal of Pharmacy and Technology. 2020 Jun1; 13(6): 2819-2824. doi: 10.5958/0974-360X.2020.00502.8.
12.    Xin Li, Huan Tong, Bing Xu, Yang Deng, Yuan Li, Junchen Huang, Yong Mao, Mengqin Liu, Ping Zhang & Siwei Guo . A sensitive and high-throughput LC-ESI-MS/MS method to detect budesonide in human plasma: application to an evaluation of pharmacokinetics of budesonide intranasal formulations with and without charcoal-block in healthy volunteers, Drug Development and Industrial Pharmacy. 2021 Feb 01; 47(2): 329-336.DOI: 10.1080/03639045.2021.1879842.

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

1.3
2021CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank


Recent Articles




Tags


Not Available